Cannabinoid receptor type 2 activation in atherosclerosis and acute cardiovascular diseases

Current Medicinal Chemistry

Volumn 21, Issue 35, 2014, Pages 4046-4058

  Carbone, Federico ^a,b   Mach, François ^a   Vuilleumier, Nicolas ^c   Montecucco, Fabrizio ^a,b,c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Atherosclerosis; Cannabinoids; CB2; Ischemia reperfusion injury; Ischemic stroke

Indexed keywords

CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST;

ACUTE DISEASE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRAIN ISCHEMIA; DISEASE COURSE; HUMAN; IN VIVO STUDY; ISCHEMIC HEART DISEASE; NONHUMAN; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; DISEASE MODEL; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; CANNABINOID RECEPTOR AGONISTS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; HUMANS; MYOCARDIAL REPERFUSION INJURY; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION; STROKE;

EID: 84928921500     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140915141332     Document Type: Article

References (131)

1. Aggarwal, S. K.; Carter, G. T.; Sullivan, M. D.; Zum Brunnen, C.; Morrill, R.; Mayer, J. D. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J. Opioid. Manag., 2009, 5(3), 153-168.
2. Mechoulam, R.; Gaoni, Y. A Total Synthesis of Dl-Delta-1-Tetrahydrocannabinol, the Active Constituent of Hashish. J. Am. Chem. Soc., 1965, 87, 3273-3275.
3. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258(5090), 1946-1949.
4. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almog, S.; Martin, B. R.; Compton, D. R.; et al., Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 1995, 50(1), 83-90.
5. Pertwee, R. G. Cannabinoid Receptor Ligands. Tocris Bioscience Scienific Review Series. http://www.tocris.com.
6. Pacher, P.; Mechoulam, R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog. Lipid Res., 2011, 50(2), 193-211.
7. Monteleone, P.; Maj, M. Dysfunctions of leptin, ghrelin, BDNF and endocannabinoids in eating disorders: beyond the homeostatic control of food intake. Psychoneuroendocrinology, 2013, 38(3), 312-330.
8. Silvestri, C.; Di Marzo, V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell. Metab., 2013, 17(4), 475-490.
9. Bennetzen, M. F.; Nielsen, M. P.; Richelsen, B.; Pedersen, S. B. Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats. Obesity (Silver Spring), 2008, 16(11), 2451-2455.
10. Li, Z.; Schmidt, S. F.; Friedman, J. M. Developmental role for endocannabinoid signaling in regulating glucose metabolism and growth. Diabetes, 2013, 62(7), 2359-2367.
11. Zubrzycki, M.; Liebold, A.; Janecka, A.; Zubrzycka, M. A new face of endocannabinoids in pharmacotherapy. Part I: protective role of endocannabinoids in hypertension and myocardial infarction. J. Physiol. Pharmacol., 2014, 65(2), 171-181.
12. Zubrzycki, M.; Liebold, A.; Janecka, A.; Zubrzycka, M. A new face of endocannabinoids in pharmacotherapy. Part II: role of endocannabinoids in inflammation-derived cardiovaascular diseases. J. Physiol. Pharmacol., 2014, 65(2), 183-191.
13. Ronco, A. M.; Llanos, M.; Tamayo, D.; Hirsch, S. Anandamide inhibits endothelin-1 production by human cultured endothelial cells: a new vascular action of this endocannabinoid. Pharmacology, 2007, 79(1), 12-16.
14. Rajesh, M.; Mukhopadhyay, P.; Hasko, G.; Huffman, J. W.; Mackie, K.; Pacher, P. CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br. J. Pharmacol., 2008, 153(2), 347-357.
15. Defer, N.; Wan, J.; Souktani, R.; Escoubet, B.; Perier, M.; Caramelle, P.; Manin, S.; Deveaux, V.; Bourin, M. C.; Zimmer, A.; Lotersztajn, S.; Pecker, F.; Pavoine, C. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. Faseb J., 2009, 23(7), 2120-2130.
16. Montecucco, F.; Di Marzo, V.; Da Silva, R. F.; Vuilleumier, N.; Capettini, L.; Lenglet, S.; Pagano, S.; Piscitelli, F.; Quintao, S.; Bertolotto, M.; Pelli, G.; Galan, K.; Pilet, L.; Kuzmanovic, K.; Burger, F.; Pane, B.; Spinella, G.; Braunersreuther, V.; Gayet-Ageron, A.; Pende, A.; Viviani, G. L.; Palombo, D.; Dallegri, F.; Roux-Lombard, P.; Santos, R. A.; Stergiopulos, N.; Steffens, S.; Mach, F. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur. Heart J., 2012, 33(7), 846-856.
17. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Le Fur, G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 1995, 232(1), 54-61.
18. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365(6441), 61-65.
19. Zheng, C.; Chen, L.; Chen, X.; He, X.; Yang, J.; Shi, Y.; Zhou, N. The second intracellular loop of the human cannabinoid CB2 receptor governs G protein coupling in coordination with the carboxyl terminal domain. PLoS One, 2013, 8(5), e63262.
20. Rhee, M. H.; Bayewitch, M.; Avidor-Reiss, T.; Levy, R.; Vogel, Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J. Neurochem., 1998, 71(4), 1525-1534.
21. Wang, T.; Brown, M. J. Differential expression of adenylyl cyclase subtypes in human cardiovascular system. Mol. Cell. Endocrinol., 2004, 223(1-2), 55-62.
22. Lepicier, P.; Bibeau-Poirier, A.; Lagneux, C.; Servant, M. J.; Lamontagne, D. Signaling pathways involved in the cardioprotective effects of cannabinoids. J. Pharmacol. Sci., 2006, 102(2), 155-166.
23. Rajesh, M.; Mukhopadhyay, P.; Batkai, S.; Patel, V.; Saito, K.; Matsumoto, S.; Kashiwaya, Y.; Horvath, B.; Mukhopadhyay, B.; Becker, L.; Hasko, G.; Liaudet, L.; Wink, D. A.; Veves, A.; Mechoulam, R.; Pacher, P. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J. Am. Coll. Cardiol., 2010, 56(25), 2115-2125.
24. Wang, Y.; Ma, S.; Wang, Q.; Hu, W.; Wang, D.; Li, X.; Su, T.; Qin, X.; Zhang, X.; Ma, K.; Chen, J.; Xiong, L.; Cao, F. Effects of cannabinoid receptor type 2 on endogenous myocardial regeneration by activating cardiac progenitor cells in mouse infarcted heart. Sci. China Life Sci., 2014, 57(2), 201-208.
25. Castaneda, J. T.; Harui, A.; Kiertscher, S. M.; Roth, J. D.; Roth, M. D. Differential expression of intracellular and extracellular CB (2) cannabinoid receptor protein by human peripheral blood leukocytes. J. Neuroimmune Pharmacol., 2013, 8(1), 323-332.
26. Herring, A. C.; Koh, W. S.; Kaminski, N. E. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid. Biochem. Pharmacol., 1998, 55(7), 1013-1023.
27. Herring, A. C.; Kaminski, N. E. Cannabinol-mediated inhibition of nuclear factor-kappaB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes. J. Pharmacol. Exp. Ther., 1999, 291(3), 1156-1163.
28. Kurihara, R.; Tohyama, Y.; Matsusaka, S.; Naruse, H.; Kinoshita, E.; Tsujioka, T.; Katsumata, Y.; Yamamura, H. Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. J. Biol. Chem., 2006, 281(18), 12908-12918.
29. Ritter, S. L.; Hall, R. A. Fine-tuning of GPCR activity by receptorinteracting proteins. Nat. Rev. Mol. Cell. Biol., 2009, 10(12), 819-830.
30. Satoh, K.; Fukumoto, Y.; Shimokawa, H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am. J. Physiol. Heart Circ. Physiol., 2011, 301(2), H287-296.
31. Derocq, J. M.; Jbilo, O.; Bouaboula, M.; Segui, M.; Clere, C.; Casellas, P. Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J. Biol. Chem., 2000, 275(21), 15621-15628.
32. Newton, C. A.; Chou, P. J.; Perkins, I.; Klein, T. W. CB (1) and CB (2) cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection. J. Neuroimmune Pharmacol., 2009, 4(1), 92-102.
33. Rajesh, M.; Mukhopadhyay, P.; Batkai, S.; Hasko, G.; Liaudet, L.; Huffman, J. W.; Csiszar, A.; Ungvari, Z.; Mackie, K.; Chatterjee, S.; Pacher, P. CB2-receptor stimulation attenuates TNF-alphainduced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am. J. Physiol. Heart Circ. Physiol., 2007, 293(4), H2210-2218.
34. Correa, F.; Hernangomez, M.; Mestre, L.; Loria, F.; Spagnolo, A.; Docagne, F.; Di Marzo, V.; Guaza, C. Anandamide enhances IL-10 production in activated microglia by targeting CB (2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia, 2010, 58(2), 135-147.
35. Ouyang, Y.; Hwang, S. G.; Han, S. H.; Kaminski, N. E. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. Mol. Pharmacol., 1998, 53(4), 676-683.
36. Kaplan, B. L.; Ouyang, Y.; Rockwell, C. E.; Rao, G. K.; Kaminski, N. E. 2-Arachidonoyl-glycerol suppresses interferon-gamma production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2. J. Leukoc. Biol., 2005, 77(6), 966-974.
37. Kaplan, B. L.; Springs, A. E.; Kaminski, N. E. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem. Pharmacol., 2008, 76(6), 726-737.
38. Kenakin, T.; Miller, L. J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev., 2010, 62(2), 265-304.
39. Jan, T. R.; Kaminski, N. E. Role of mitogen-activated protein kinases in the differential regulation of interleukin-2 by cannabinol. J. Leukoc. Biol., 2001, 69(5), 841-849.
40. Jan, T. R.; Rao, G. K.; Kaminski, N. E. Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity. Mol. Pharmacol., 2002, 61(2), 446-454.
41. Atwood, B. K.; Mackie, K. CB2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol., 2010, 160(3), 467-479.
42. Nevalainen, T.; Irving, A. J. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? Curr. Top. Med. Chem., 2010, 10(8), 799-813.
43. Irving, A. New blood brothers: the GPR55 and CB2 partnership. Cell. Res., 2011, 21(10), 1391-1392.
44. Anavi-Goffer, S.; Baillie, G.; Irving, A. J.; Gertsch, J.; Greig, I. R.; Pertwee, R. G.; Ross, R. A. Modulation of L-alphalysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J. Biol. Chem., 2012, 287(1), 91-104.
45. Sharir, H.; Console-Bram, L.; Mundy, C.; Popoff, S. N.; Kapur, A.; Abood, M. E. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. J. Neuroimmune Pharmacol., 2012, 7(4), 856-865.
46. Balenga, N. A.; Martinez-Pinilla, E.; Kargl, J.; Schroder, R.; Peinhaupt, M.; Platzer, W.; Balint, Z.; Zamarbide, M.; Dopeso-Reyes, I.; Ricobaraza, A.; Perez-Ortiz, J. M.; Kostenis, E.; Waldhoer, M.; Heinemann, A.; Franco, R. Heteromerization of GPR55 and cannabinoid CB receptors modulates signaling. Br. J. Pharmacol., 2014, doi: 10.1111/bph.12850.
47. Balenga, N. A.; Aflaki, E.; Kargl, J.; Platzer, W.; Schroder, R.; Blattermann, S.; Kostenis, E.; Brown, A. J.; Heinemann, A.; Waldhoer, M. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell. Res., 2011, 21(10), 1452-1469.
48. 2+-activated large-conductance K+ channels in endothelial cells. Pflugers Arch., 2011, 461(1), 177-189.
49. Libby, P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2012, 32(9), 2045-2051.
50. 2+ in endothelial cells. Br. J. Pharmacol., 1999, 126(7), 1593-1600.
51. 2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. Br. J. Pharmacol., 2003, 140(8), 1351-1362.
52. Kargl, J.; Brown, A. J.; Andersen, L.; Dorn, G.; Schicho, R.; Waldhoer, M.; Heinemann, A. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J. Pharmacol. Exp. Ther., 2013, 346(1), 54-66.
53. Offertaler, L.; Mo, F. M.; Batkai, S.; Liu, J.; Begg, M.; Razdan, R. K.; Martin, B. R.; Bukoski, R. D.; Kunos, G. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol., 2003, 63(3), 699-705.
54. Bondarenko, A. I. Endothelial atypical cannabinoid receptor: do we have enough evidence? Br. J. Pharmacol., 2014,. doi: 10.1111/bph.12866.
55. Mestre, L.; Correa, F.; Docagne, F.; Clemente, D.; Guaza, C. The synthetic cannabinoid WIN 55, 212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem. Pharmacol., 2006, 72(7), 869-880.
56. McCollum, L.; Howlett, A. C.; Mukhopadhyay, S. Anandamidemediated CB1/CB2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothelial cells. J. Pharmacol. Exp. Ther., 2007, 321(3), 930-937.
57. Ni, X.; Geller, E. B.; Eppihimer, M. J.; Eisenstein, T. K.; Adler, M. W.; Tuma, R. F. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult. Scler., 2004, 10(2), 158-164.
58. Mestre, L.; Docagne, F.; Correa, F.; Loria, F.; Hernangomez, M.; Borrell, J.; Guaza, C. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol. Cell. Neurosci., 2009, 40(2), 258-266.
59. Zhao, Y.; Yuan, Z.; Liu, Y.; Xue, J.; Tian, Y.; Liu, W.; Zhang, W.; Shen, Y.; Xu, W.; Liang, X.; Chen, T., Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. J. Cardiovasc. Pharmacol., 2010, 55(3), 292-298.
60. Ramirez, S. H.; Hasko, J.; Skuba, A.; Fan, S.; Dykstra, H.; McCormick, R.; Reichenbach, N.; Krizbai, I.; Mahadevan, A.; Zhang, M.; Tuma, R.; Son, Y. J.; Persidsky, Y. Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J. Neurosci., 2012, 32(12), 4004-4016.
61. Schwartzfarb, L.; Needle, M.; Chavez-Chase, M. Dose-related inhibition of leukocyte migration by marihuana and delta-9-tetrahydrocannabinol (THC) in vitro. J. Clin. Pharmacol., 1974, 14(1), 35-41.
62. Sacerdote, P.; Massi, P.; Panerai, A. E.; Parolaro, D. In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J. Neuroimmunol., 2000, 109(2), 155-163.
63. Sacerdote, P.; Martucci, C.; Vaccani, A.; Bariselli, F.; Panerai, A. E.; Colombo, A.; Parolaro, D.; Massi, P. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J. Neuroimmunol., 2005, 159(1-2), 97-105.
64. Raborn, E. S.; Marciano-Cabral, F.; Buckley, N. E.; Martin, B. R.; Cabral, G. A. The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. J. Neuroimmune Pharmacol., 2008, 3(2), 117-129.
65. Montecucco, F.; Burger, F.; Mach, F.; Steffens, S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am. J. Physiol. Heart Circ. Physiol., 2008, 294(3), H1145-1155.
66. Molica, F.; Matter, C. M.; Burger, F.; Pelli, G.; Lenglet, S.; Zimmer, A.; Pacher, P.; Steffens, S. Cannabinoid receptor CB2 protects against balloon-induced neointima formation. Am. J. Physiol. Heart Circ. Physiol., 2012, 302(5), H1064-1074.
67. Iwamura, H.; Suzuki, H.; Ueda, Y.; Kaya, T.; Inaba, T. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J. Pharmacol. Exp. Ther., 2001, 296(2), 420-425.
68. Ueda, Y.; Miyagawa, N.; Matsui, T.; Kaya, T.; Iwamura, H. Involvement of cannabinoid CB (2) receptor-mediated response and efficacy of cannabinoid CB (2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur. J. Pharmacol., 2005, 520(1-3), 164-171.
69. Dhopeshwarkar, A.; Mackie, K. CB2 cannabinoid receptors as a therapeutic target - What does the future hold? Mol. Pharmacol., 2014, 86(4), 430-437.
70. Hao, M. X.; Jiang, L. S.; Fang, N. Y.; Pu, J.; Hu, L. H.; Shen, L. H.; Song, W.; He, B. The cannabinoid WIN55, 212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages. J. Lipid Res., 2010, 51(8), 2181-2190.
71. Chiurchiu, V.; Lanuti, M.; Catanzaro, G.; Fezza, F.; Rapino, C.; Maccarrone, M. Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and antiinflammatory role of type-2 cannabinoid receptor. Atherosclerosis, 2014, 233(1), 55-63.
72. Trinchieri, G.; Pflanz, S.; Kastelein, R. A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity, 2003, 19(5), 641-644.
73. Tsiantoulas, D.; Diehl, C. J.; Witztum, J. L.; Binder, C. J. B cells and humoral immunity in atherosclerosis. Circ. Res., 2014, 114(11), 1743-1756.
74. Joseph, J.; Niggemann, B.; Zaenker, K. S.; Entschladen, F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol. Immunother., 2004, 53(8), 723-728.
75. Ghosh, S.; Preet, A.; Groopman, J. E.; Ganju, R. K. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol. Immunol., 2006, 43(14), 2169-2179.
76. Coopman, K.; Smith, L. D.; Wright, K. L.; Ward, S. G. Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. Int. Immunopharmacol., 2007, 7(3), 360-371.
77. Ziring, D.; Wei, B.; Velazquez, P.; Schrage, M.; Buckley, N. E.; Braun, J. Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics, 2006, 58(9), 714-725.
78. Yuan, M.; Kiertscher, S. M.; Cheng, Q.; Zoumalan, R.; Tashkin, D. P.; Roth, M. D. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol., 2002, 133(1-2), 124-131.
79. Cencioni, M. T.; Chiurchiu, V.; Catanzaro, G.; Borsellino, G.; Bernardi, G.; Battistini, L.; Maccarrone, M. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One, 2010, 5(1), e8688.
80. Guillot, A.; Hamdaoui, N.; Bizy, A.; Zoltani, K.; Souktani, R.; Zafrani, E. S.; Mallat, A.; Lotersztajn, S.; Lafdil, F. Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver. Hepatology, 2014, 59(1), 296-306.
81. Springs, A. E.; Karmaus, P. W.; Crawford, R. B.; Kaplan, B. L.; Kaminski, N. E., Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol. J. Leukoc. Biol., 2008, 84(6), 1574-1584.
82. Servettaz, A.; Kavian, N.; Nicco, C.; Deveaux, V.; Chereau, C.; Wang, A.; Zimmer, A.; Lotersztajn, S.; Weill, B.; Batteux, F. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am. J. Pathol., 2010, 177(1), 187-196.
83. Basu, S.; Ray, A.; Dittel, B. N. Cannabinoid Receptor 2 (CB2) Plays a Role in the Generation of Germinal Center and Memory B Cells, but Not in the Production of Antigen-Specific IgG and IgM, in Response to T-dependent Antigens. PLoS One, 2013, 8(6), e67587.
84. Feng, R.; Milcarek, C. A.; Xie, X. Q. Antagonism of cannabinoid receptor 2 pathway suppresses IL-6-induced immunoglobulin IgM secretion. BMC Pharmacol. Toxicol., 2014, 15, 30.
85. Carbone, F.; Nencioni, A.; Mach, F.; Vuilleumier, N.; Montecucco, F. Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases. Thromb. Haemost., 2013, 109(5), 854-868.
86. Ait-Oufella, H.; Sage, A. P.; Mallat, Z.; Tedgui, A. Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ. Res., 2014, 114(10), 1640-1660.
87. Adhikary, S.; Kocieda, V. P.; Yen, J. H.; Tuma, R. F.; Ganea, D. Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood, 2012, 120(18), 3741-3749.
88. Steffens, S.; Veillard, N. R.; Arnaud, C.; Pelli, G.; Burger, F.; Staub, C.; Karsak, M.; Zimmer, A.; Frossard, J. L.; Mach, F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature, 2005, 434(7034), 782-786.
89. Montecucco, F.; Matias, I.; Lenglet, S.; Petrosino, S.; Burger, F.; Pelli, G.; Braunersreuther, V.; Mach, F.; Steffens, S.; Di Marzo, V. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis, 2009, 205(2), 433-441.
90. Netherland, C. D.; Pickle, T. G.; Bales, A.; Thewke, D. P. Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis, 2010, 213(1), 102-108.
91. Zhao, Y.; Liu, Y.; Zhang, W.; Xue, J.; Wu, Y. Z.; Xu, W.; Liang, X.; Chen, T.; Kishimoto, C.; Yuan, Z. WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice. Eur. J. Pharmacol., 2010, 649(1-3), 285-292.
92. Willecke, F.; Zeschky, K.; Ortiz Rodriguez, A.; Colberg, C.; Auwarter, V.; Kneisel, S.; Hutter, M.; Lozhkin, A.; Hoppe, N.; Wolf, D.; Von Zur Muhlen, C.; Moser, M.; Hilgendorf, I.; Bode, C.; Zirlik, A. Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice. PLoS One, 2011, 6(4), e19405.
93. Delsing, D. J.; Leijten, F. P.; Arts, K.; Van Eenennaam, H.; Garritsen, A.; Gijbels, M. J.; De Winther, M. P.; Van Elsas, A. Cannabinoid Receptor 2 Deficiency in Haematopoietic cells Aggravates Early Atherosclerosis in LDL Receptor Deficient Mice. Open Cardiovasc. Med. J., 2011, 5, 15-21.
94. Hoyer, F. F.; Steinmetz, M.; Zimmer, S.; Becker, A.; Lutjohann, D.; Buchalla, R.; Zimmer, A.; Nickenig, G. Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J. Mol. Cell. Cardiol., 2011, 51(6), 1007-1014.
95. Libby, P.; Tabas, I.; Fredman, G.; Fisher, E. A. Inflammation and its resolution as determinants of acute coronary syndromes. Circ. Res., 2014, 114(12), 1867-1879.
96. Christia, P.; Frangogiannis, N. G. Targeting inflammatory pathways in myocardial infarction. Eur. J. Clin. Invest., 2013, 43(9), 986-995.
97. Catani, M. V.; Gasperi, V.; Catanzaro, G.; Baldassarri, S.; Bertoni, A.; Sinigaglia, F.; Avigliano, L.; Maccarrone, M. Human platelets express authentic CB (1) and CB (2) receptors. Curr. Neurovasc. Res., 2010, 7(4), 311-318.
98. Brantl, S. A.; Khandoga, A. L.; Siess, W. Mechanism of platelet activation induced by endocannabinoids in blood and plasma. Platelets, 2014, 25(3), 151-161.
99. Inoue, T.; Croce, K.; Morooka, T.; Sakuma, M.; Node, K.; Simon, D. I. Vascular inflammation and repair: implications for reendothelialization, restenosis, and stent thrombosis. JACC Cardiovasc. Interv., 2011, 4(10), 1057-1066.
100. Swirski, F. K.; Nahrendorf, M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science, 2013, 339(6116), 161-166.
101. Carbone, F.; Nencioni, A.; Mach, F.; Vuilleumier, N.; Montecucco, F. Pathophysiological role of neutrophils in acute myocardial infarction. Thromb. Haemost., 2013, 110(3), 501-514.
102. Shmist, Y. A.; Goncharov, I.; Eichler, M.; Shneyvays, V.; Isaac, A.; Vogel, Z.; Shainberg, A. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol. Cell. Biochem., 2006, 283(1-2), 75-83.
103. Li, Q.; Guo, H. C.; Maslov, L. N.; Qiao, X. W.; Zhou, J. J.; Zhang, Y. Mitochondrial permeability transition pore plays a role in the cardioprotection of CB2 receptor against ischemia-reperfusion injury. Can. J. Physiol. Pharmacol., 2014, 92(3), 205-214.
104. Lagneux, C.; Lamontagne, D. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br. J. Pharmacol., 2001, 132(4), 793-796.
105. Joyeux, M.; Arnaud, C.; Godin-Ribuot, D.; Demenge, P.; Lamontagne, D.; Ribuot, C. Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc. Res., 2002, 55(3), 619-625.
106. Bouchard, J. F.; Lepicier, P.; Lamontagne, D. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci., 2003, 72(16), 1859-1870.
107. Lepicier, P.; Bouchard, J. F.; Lagneux, C.; Lamontagne, D. Endocannabinoids protect the rat isolated heart against ischaemia. Br. J. Pharmacol., 2003, 139(4), 805-815.
108. Krylatov, A. V.; Ugdyzhekova, D. S.; Bernatskaya, N. A.; Maslov, L. N.; Mekhoulam, R.; Pertwee, R. G.; Stephano, G. B. Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull. Exp. Biol. Med., 2001, 131(6), 523-525.
109. Di Filippo, C.; Rossi, F.; Rossi, S.; D'Amico, M. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J. Leukoc. Biol., 2004, 75(3), 453-459.
110. Underdown, N. J.; Hiley, C. R.; Ford, W. R. Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br. J. Pharmacol., 2005, 146(6), 809-816.
111. Hajrasouliha, A. R.; Tavakoli, S.; Ghasemi, M.; Jabehdar-Maralani, P.; Sadeghipour, H.; Ebrahimi, F.; Dehpour, A. R. Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart. Eur. J. Pharmacol., 2008, 579(1-3), 246-252.
112. Montecucco, F.; Lenglet, S.; Braunersreuther, V.; Burger, F.; Pelli, G.; Bertolotto, M.; Mach, F.; Steffens, S. CB (2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J. Mol. Cell. Cardiol., 2009, 46(5), 612-620.
113. Wang, P. F.; Jiang, L. S.; Bu, J.; Huang, X. J.; Song, W.; Du, Y. P.; He, B. Cannabinoid-2 receptor activation protects against infarct and ischemia-reperfusion heart injury. J. Cardiovasc. Pharmacol., 2012, 59(4), 301-307.
114. Li, Q.; Wang, F.; Zhang, Y. M.; Zhou, J. J.; Zhang, Y. Activation of cannabinoid type 2 receptor by JWH133 protects heart against ischemia/reperfusion-induced apoptosis. Cell. Physiol. Biochem., 2013, 31(4-5), 693-702.
115. Duerr, G. D.; Heinemann, J. C.; Suchan, G.; Kolobara, E.; Wenzel, D.; Geisen, C.; Matthey, M.; Passe-Tietjen, K.; Mahmud, W.; Ghanem, A.; Tiemann, K.; Alferink, J.; Burgdorf, S.; Buchalla, R.; Zimmer, A.; Lutz, B.; Welz, A.; Fleischmann, B. K.; Dewald, O. The endocannabinoid-CB2 receptor axis protects the ischemic heart at the early stage of cardiomyopathy. Basic Res. Cardiol., 2014, 109(4), 425. doi: 10.1007/s00395-014-0425-x.
116. Duerr, G. D.; Heinemann, J. C.; Dunkel, S.; Zimmer, A.; Lutz, B.; Lerner, R.; Roell, W.; Mellert, F.; Probst, C.; Esmailzadeh, B.; Welz, A.; Dewald, O. Myocardial hypertrophy is associated with inflammation and activation of endocannabinoid system in patients with aortic valve stenosis. Life Sci., 2013, 92(20-21), 976-983.
117. Walter, L.; Stella, N. Cannabinoids and neuroinflammation. Br. J. Pharmacol., 2004, 141(5), 775-785.
118. Maresz, K.; Carrier, E. J.; Ponomarev, E. D.; Hillard, C. J.; Dittel, B. N. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem., 2005, 95(2), 437-445.
119. Ehrhart, J.; Obregon, D.; Mori, T.; Hou, H.; Sun, N.; Bai, Y.; Klein, T.; Fernandez, F.; Tan, J.; Shytle, R. D. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation, 2005, 2, 29.
120. Ribeiro, R.; Wen, J.; Li, S.; Zhang, Y. Involvement of ERK1/2, cPLA2 and NF-kappaB in microglia suppression by cannabinoid receptor agonists and antagonists. Prostaglandins Other Lipid Mediat., 2013, 100-101, 1-14.
121. Carrier, E. J.; Kearn, C. S.; Barkmeier, A. J.; Breese, N. M.; Yang, W.; Nithipatikom, K.; Pfister, S. L.; Campbell, W. B.; Hillard, C. J. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol. Pharmacol., 2004, 65(4), 999-1007.
122. Ashton, J. C.; Rahman, R. M.; Nair, S. M.; Sutherland, B. A.; Glass, M.; Appleton, I. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci. Lett., 2007, 412(2), 114-117.
123. Zhang, M.; Martin, B. R.; Adler, M. W.; Razdan, R. K.; Jallo, J. I.; Tuma, R. F. Cannabinoid CB (2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J. Cereb. Blood Flow Metab., 2007, 27(7), 1387-1396.
124. Zhang, M.; Martin, B. R.; Adler, M. W.; Razdan, R. K.; Ganea, D.; Tuma, R. F. Modulation of the balance between cannabinoid CB (1) and CB (2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience, 2008, 152(3), 753-760.
125. Murikinati, S.; Juttler, E.; Keinert, T.; Ridder, D. A.; Muhammad, S.; Waibler, Z.; Ledent, C.; Zimmer, A.; Kalinke, U.; Schwaninger, M. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. Faseb J., 2010, 24(3), 788-798.
126. Fernandez-Lopez, D.; Faustino, J.; Derugin, N.; Wendland, M.; Lizasoain, I.; Moro, M. A.; Vexler, Z. S. Reduced infarct size and accumulation of microglia in rats treated with WIN 55, 212-2 after neonatal stroke. Neuroscience, 2012, 207, 307-315.
127. Choi, I. Y.; Ju, C.; Anthony Jalin, A. M.; Lee Da, I.; Prather, P. L.; Kim, W. K. Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury. Am. J. Pathol., 2013, 182(3), 928-939.
128. Miller, A. M.; Stella, N. CB2 receptor-mediated migration of immune cells: it can go either way. Br. J. Pharmacol., 2008, 153(2), 299-308.
129. Whiteside, G. T.; Lee, G. P.; Valenzano, K. J. The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr. Med. Chem., 2007, 14(8), 917-936.
130. Pacher, P.; Kunos, G. Modulating the endocannabinoid system in human health and disease-successes and failures. Febs J., 2013, 280(9), 1918-1943.
131. Van Rooy, M. J.; Pretorius, E. Obesity, hypertension and hypercholesterolemia as risk factors for atherosclerosis leading to ischemic events. Curr. Med. Chem., 2014, 21(19), 2121-2129.